New drug aims to stop hidden lymphoma cells from returning
NCT ID NCT06670105
First seen Nov 01, 2025 · Last updated Jun 15, 2026 · Updated 34 times
Summary
This study was designed to see if the drug glofitamab can stop large B-cell lymphoma from returning in patients who are in complete remission but still have tiny traces of the disease (called minimal residual disease). The trial planned to enroll adults who completed standard chemotherapy and tested positive for these leftover cancer cells. However, the study was withdrawn before any participants were enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
The University of Texas M. D. Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.